SAT0255 A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosus
V. Werth(University of Pennsylvania), Douglas R. Hough(Bristol-Myers Squibb (United States)), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Ada Azaryan(Unknown), Shimon Korish(Bristol-Myers Squibb (United States)), Richard Furie(Hofstra University), Seuk Keun Choi, PH Schafer, Michael Weiswasser(Bristol-Myers Squibb (United States))
Cited by 6
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478